Evommune, Inc. (EVMN) Income Statement
EVMN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsEVMN revenue and net income
Where EVMN's revenue goes
2025Each bar shows an amount and its share of revenue. EVMN kept −529.8% of revenue as net income.
EVMN profit margins
EVMN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +85.7% | — | — | — |
| Gross profit | +127.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EVMN quarterly EPS vs estimates
Evommune beat the analyst EPS estimate in 2 of the last 4 quarters. Next report: December 10, 2026 (estimate $-0.82).
EVMN income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $13.0M | $7.0M | $5.0M |
| Cost of revenue | $1.4M | $1.3M | $1.0M |
| Gross profit | $13.0M | $5.7M | $4.0M |
| Research & development | $74.0M | $64.2M | $32.0M |
| Sales, general & admin | $20.0M | — | — |
| Total operating expenses | $94.1M | $75.7M | $41.9M |
| Operating income | −$81.1M | −$70.0M | −$37.9M |
| Interest income | $3.3M | — | — |
| Interest expense | $7,000 | $34,000 | $58,000 |
| Income before taxes | −$68.9M | −$66.8M | −$34.1M |
| Net income | −$68.9M | −$66.8M | −$34.1M |
| EBITDA | −$67.5M | −$65.5M | −$33.0M |
| EPS (diluted) | −$9.50 | −$2.22 | — |
| Gross margin | 100.0% | 81.6% | 80.0% |
| Operating margin | −623.6% | −1,000.2% | −757.0% |
| Net margin | −529.8% | −954.4% | −681.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $10.0M | $0 | $3.0M | $0 | $0 | $0 | $7.0M |
| Cost of revenue | — | $349,000 | $326,000 | $311,000 | $375,000 | $377,000 | — | — | $325,000 | $271,000 |
| Gross profit | — | −$349,000 | −$326,000 | $10.0M | −$375,000 | $2.6M | — | — | −$325,000 | $6.7M |
| Research & development | $26.4M | $17.3M | $20.4M | $19.6M | $19.6M | $14.4M | $15.6M | $13.3M | $25.2M | $7.9M |
| Sales, general & admin | $8.5M | $6.6M | $9.3M | $3.7M | $3.4M | — | $3.4M | $3.2M | — | — |
| Total operating expenses | $34.9M | $23.6M | $29.7M | $23.3M | $22.6M | $17.7M | $19.0M | $16.5M | $28.0M | $10.5M |
| Operating income | −$34.9M | −$24.0M | −$29.7M | −$13.3M | −$23.0M | −$15.0M | −$19.0M | −$16.5M | −$28.3M | −$3.8M |
| Interest income | $2.7M | $2.3M | $1.4M | $862,000 | $403,000 | — | $727,000 | $618,000 | — | — |
| Interest expense | — | — | — | — | $3,000 | $4,000 | — | — | $9,000 | $11,000 |
| Income before taxes | −$32.2M | −$21.7M | −$28.3M | −$12.5M | −$13.6M | −$14.6M | −$18.3M | −$15.9M | −$27.4M | −$2.8M |
| Net income | −$32.2M | −$21.7M | −$28.3M | −$12.5M | −$13.6M | −$14.6M | −$18.3M | −$15.9M | −$27.4M | −$2.8M |
| EBITDA | −$34.3M | −$21.3M | −$27.9M | −$12.2M | −$13.2M | −$14.2M | −$18.0M | — | −$27.0M | −$2.5M |
| EPS (diluted) | −$0.89 | −$0.64 | −$1.43 | −$8.07 | — | — | — | — | — | — |
| Gross margin | — | — | — | 100.0% | — | 87.4% | — | — | — | 96.1% |
| Operating margin | — | — | — | −133.3% | — | −501.1% | — | — | — | −53.6% |
| Net margin | — | — | — | −124.8% | — | −485.2% | — | — | — | −39.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EVMN's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EVMN financial results
In fiscal year 2025 (ended December 31, 2025), Evommune reported revenue of $13.0 million, up 85.7% from the year before. It had a net loss of $68.9 million, a net profit margin of −529.8%. Diluted earnings per share came to −$9.50.
See the EVMN stock overview for the latest quote and news, or the EVMN chart for price history and technical indicators.
EVMN income statement FAQ
What is Evommune's annual revenue?
Evommune reported total revenue of $13.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 85.7% from $7.0 million the previous year.
Is Evommune profitable?
No. Evommune reported a net loss of $68.9 million in fiscal 2025, a net profit margin of −529.8%; its operating margin was −623.6%.
What is Evommune's gross margin?
Evommune's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Evommune kept $100 after the direct cost of its products and services.
How much does Evommune spend on research and development?
Evommune spent $74.0 million on research and development in fiscal 2025, 569.6% of revenue.
What are Evommune's earnings per share?
Evommune earned $-9.50 per diluted share in fiscal 2025, compared with $-2.22 a year earlier.
When will Evommune report its next earnings?
Evommune is expected to report results for the quarter ending September 30, 2026 on December 10, 2026.
When does Evommune's fiscal year end?
Evommune's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.